Triglav Skladi’s Dr. Reddy's Laboratories RDY Stock Holding History

Triglav Skladi’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-65,000	Closed	-$857K	–	138
2025 Q1	$857K	Buy	+65,000	New	+$897K	0.07%	101

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Triglav Skladi's RDY Position: Q2 2025 in Review

Triglav Skladi sold out of Dr. Reddy's Laboratories (RDY) in Q2 2025, closing a stake of 65,000 shares — an estimated $857K sold.

Triglav Skladi first reported a position in RDY in Q1 2025 and held it in 1 quarter. The position peaked at $857K in Q1 2025. 242 funds tracked by Wall St. Rank hold RDY as of Q2 2025.

Triglav Skladi reported no remaining Dr. Reddy's Laboratories position as of Q2 2025 after selling out during the quarter.
Triglav Skladi sold 65,000 Dr. Reddy's Laboratories shares in Q2 2025, an estimated $857K.
Triglav Skladi first reported a position in Dr. Reddy's Laboratories in Q1 2025 and held it in 1 quarter.
Triglav Skladi's Dr. Reddy's Laboratories position peaked at $857K in Q1 2025.
242 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2025.

Based on Triglav Skladi's 13F filing for Q2 2025, filed 5 Aug 2025.